Pfizer Mitigates Tanezumab Risk with Potential US$1.8 B Deal with Eli Lilly
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 11 (Table of Contents)
Published: 13 Nov-2013
DOI: 10.3833/pdr.v2013.i11.1989 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Three years after development of the entire class of nerve growth factor (NGF) inhibitors was put on clinical hold by the US FDA over serious safety concerns related to joint destruction, Pfizer has decided to continue Phase III development of its anti-NGF antibody tanezumab in collaboration with Eli Lilly as part of a deal potentially worth up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS